Pharmacytimes: Condition Center: Hepatitis C http://www.pharmacytimes.com/condition-resources/hepatitisc/condition-rss Hepatitis C en-us Tue, 17 Oct 2017 10:20:49 UTC Tue, 17 Oct 2017 10:20:49 UTC Mavyret for Hepatitis C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/10/mavyret-for-hep-c-what-pharmacists-should-know There are several key therapeutics areas of which to be aware. 5:11 AM, Tue October 3, 2017 Merck Discontinues 2 HCV Clinical Programs http://www.pharmacytimes.com/resource-centers/hepatitisc/merck-discontinues-2-hcv-clinical-programs This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier). 11:45 AM, Sat September 30, 2017 Vosevi for Hep C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/09/vosevi-for-hep-c-what-pharmacists-should-know This article highlights several key therapeutics areas with Vosevi that every pharmacist should know. 9:27 PM, Wed September 6, 2017 FDA Approves Hepatitis C Drug http://www.pharmacytimes.com/product-news/fda-approves-hepatitis-c-drug Officials with the FDA have announced the approval of glecaprevir and pibrentasvir (Mavyret, AbbVie Inc) for hepatitis C.&nbsp; 4:40 PM, Thu August 3, 2017 FDA Approves Hep C Drug http://www.pharmacytimes.com/resource-centers/hepatitisc/fda-approves-hep-c-drug- &nbsp;Vosevi is a fixed-dose, combination tablet containing&nbsp;sofosbuvir&nbsp;and velpatasvir, as well as the new drug voxilaprevir, according to a press release.<br /> &nbsp;<br /> <br /> <br /> &nbsp; 5:10 PM, Tue July 18, 2017 Hepatitis C: Oral Direct-Acting Antivirals Are Standard of Care http://www.pharmacytimes.com/publications/health-system-edition/2017/May2017/hepatitis-c-oral-directacting-antivirals-are-standard-of-care <p>Chronic hepatitis C virus (HCV) infection, estimated to affect up to 4 million Americans, is a leading cause of end-stage liver disease, hepatocellular carcinoma, and liver transplant.&nbsp;</p> 2:11 PM, Wed May 17, 2017 CDC Report Focuses on Slowing Hepatitis C Infection Rate http://www.pharmacytimes.com/news/cdc-report-focuses-on-slowing-hepatitis-c-infection-rate Hepatitis C virus infection rates are the highest in 15 years, according to recent data released by the CDC. 9:30 AM, Tue May 16, 2017 FDA Approves 2 Hepatitis C Drugs for Use in Pediatric Patients http://www.pharmacytimes.com/product-news/fda-approves-2-hepatitis-c-drugs-for-use-in-pediatric-patients The FDA approved supplemental applications for Sovaldi (sofosubuvir) and Harvoni (ledipasvir and sofosbuvir), marketed by Gilead Sciences Inc., to treat hepatitis C virus (HCV) in pediatric patients.&nbsp; 11:37 AM, Fri April 7, 2017 Hepatitis C Regimen Can Cause Cataracts http://www.pharmacytimes.com/contributor/daniel-holland-pharmd/2017/04/hepatitis-c-regimen-can-cause-cataracts An adverse effect with interferon-ribavirin Hepatitis C therapy that does not stop after discontinuation. 2:03 AM, Mon April 3, 2017 Will Hepatitis C Virus Medication Costs Drop in the Years Ahead? http://www.pharmacytimes.com/resource-centers/hepatitisc/will-hepatitis-c-virus-medicaton-costs-drop-in-the-years-ahead Proposals such as allowing Medicare price negotiation, capping out-of-pocket drug costs, importing drugs, and limiting manufacturer&rsquo; spending on patient marketing could all result in lower HCV drug costs. 5:17 PM, Wed February 8, 2017 Investigational Hepatitis C Drug Granted Priority Review http://www.pharmacytimes.com/product-news/investigational-hepatitis-c-drug-granted-priority-review &nbsp;<br /> The FDA has accepted AbbVie&rsquo;s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P).&nbsp; 2:22 PM, Fri February 3, 2017 ISMP Report Questions Safety of Hepatitis C Drugs http://www.pharmacytimes.com/news/ismp-report-questions-safety-of-hepatitis-c-drugs A recently-published Institute for Safe Medication Practices (ISMP) report details updated concerns about newer drugs used to treat hepatitis C virus (HCV).&nbsp; 11:44 AM, Fri January 27, 2017 Epclusa for Hep C: What Pharmacists Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2017/01/epclusa-for-hep-c-what-pharmacists-should-know This fixed-dose combination of sofosbuvir and velpatasvir is indicated to treat chronic HCV genotypes 1-6. 9:38 PM, Wed January 4, 2017 Studies in Virology Every Pharmacist Should Know http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/12/studies-in-virology-every-pharmacist-should-know Over the years, a number of landmark clinical studies in virology have been published, shaping how we treat the disease today. 10:35 PM, Tue December 27, 2016 These Treatments Improve PHT in Patients With HIV and HCV http://www.pharmacytimes.com/resource-centers/hiv/these-treatments-improve-pht-in-patients-with-hiv-and-hcv Patients who have human immunodeficiency virus (HIV) infection are at elevated risk for HCV. 3:04 PM, Tue December 13, 2016 Declining Hepatitis C Sales http://www.pharmacytimes.com/contributor/jason-poquette/2016/11/declining-hepatitis-c-sales-failure-or-success Reports show that sales and revenue from Hepatitis C treatments are declining. What does this mean for patients? 10:28 PM, Wed November 16, 2016 Pharmacist Charged for Hepatitis C Drug Fraud http://www.pharmacytimes.com/news/pharmacist-charged-for-hepatitis-c-drug-fraud A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016. 8:00 AM, Thu October 27, 2016 5 Highlights from the Pharmacy World This Week http://www.pharmacytimes.com/contributor/charles-ng-pharmd-mba-candidate-2017/2016/10/5-highlights-from-the-pharmacy-world-this-week In case you missed it, here's the hottest news in pharmacy this week: 11:13 PM, Thu October 6, 2016 Trouble on the Horizon for Gilead's HCV Market Hold http://www.pharmacytimes.com/contributor/austin-hewlett-pharmd-mba-candidate/2016/09/trouble-on-the-horizon-for-gileads-hcv-market-hold Gilead Sciences maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa has come under increasing scrutiny for declining revenues, both in the near-term and beyond. 3:05 AM, Fri September 2, 2016 Managing Drug Interactions in HIV/HCV-Coinfected Patients http://www.pharmacytimes.com/contributor/timothy-o-shea/2016/08/managing-drug-interactions-in-hiv-hcv-coinfected-patients Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions. 3:19 AM, Tue August 23, 2016